Pharvaris (NASDAQ:PHVS) Stock: Insider David Nassif Sells 6,000 Shares

Pharvaris N.V. (NASDAQ:PHVS) CFO David Nassif sold 6,000 shares of Pharvaris stock in a transaction on Monday, September 21st. The shares were sold at an average price of $36.47, for a total transaction of $218,820.00. Following the completion of the transaction, the chief financial officer owned 114,300 shares in the company, valued at approximately $4,168,521. This represents a 4.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Pharvaris Stock Down 0.2%

Shares of PHVS stock opened at $32.99 on Friday. The stock has a market capitalization of $2.16 billion, a PE ratio of -10.82 and a beta of -2.33. Pharvaris N.V. has a 52-week low of $20.65 and a 52-week high of $43.25. The stock’s 50-day moving average price is $35.35 and its 200 day moving average price is $31.98.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.06). Analysts expect that Pharvaris N.V. will post -3.12 earnings per share for the current fiscal year.

Key Headlines Impacting Pharvaris

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Analyst sentiment remains supportive: Wells Fargo, Cantor Fitzgerald, Leerink Partners and Citizens JMP maintain positive ratings, with several raising price targets to $65–$79. The consensus rating is “Moderate Buy,” with an average target of $59.87. Pharvaris analyst ratings and insider trading report
• Positive Sentiment: Institutional ownership trends were favorable, including a new approximately $160.6 million position by venBio Partners, a 12.9% increase by Wellington Management and a 144.6% increase by Seven Fleet Capital. These purchases may signal confidence in Pharvaris’ oral hereditary angioedema treatment platform.
• Neutral Sentiment: Reported short interest was listed at zero shares as of September 24, implying no days-to-cover and little evidence of meaningful short-selling pressure. However, the figure may reflect a reporting or data anomaly given the company’s trading volume.
• Negative Sentiment: Several executives sold shares. CFO David Nassif sold 6,000 shares for approximately $218,820, while Director Johannes Gerardus Chri Schikan sold 800 shares in a separate filing. Additional reports cited sales of 200,000 shares by Schikan, 52,500 by Elisabeth Bjork and 100,000 by Peng Lu. The cluster of insider selling could weigh on sentiment, although executives retained sizable holdings. Pharvaris insider selling report
• Negative Sentiment: Pharvaris remains loss-making and recently reported a quarterly loss of $0.81 per share, wider than the $0.75 analyst estimate. Analysts expect a full-year loss of approximately $3.12 per share, leaving the stock dependent on clinical and regulatory progress for further upside.

Institutional Investors Weigh In On Pharvaris

A number of institutional investors have recently bought and sold shares of PHVS. venBio Partners LLC purchased a new stake in shares of Pharvaris during the 2nd quarter worth about $160,569,809. 5AM Venture Management LLC purchased a new position in Pharvaris in the second quarter valued at approximately $27,581,008. BlackRock Inc. acquired a new position in Pharvaris during the second quarter valued at approximately $26,677,000. Elmind Capital LP acquired a new position in Pharvaris during the second quarter valued at approximately $18,180,435. Finally, Seven Fleet Capital Management LP grew its stake in Pharvaris by 144.6% during the second quarter. Seven Fleet Capital Management LP now owns 774,501 shares of the company’s stock worth $26,782,000 after buying an additional 457,804 shares during the period.

Analyst Upgrades and Downgrades

PHVS has been the topic of several recent research reports. Morgan Stanley upped their price target on shares of Pharvaris from $46.00 to $62.00 and gave the company an “overweight” rating in a report on Wednesday, September 9th. Guggenheim lifted their price objective on Pharvaris from $40.00 to $44.00 and gave the stock a “buy” rating in a research report on Thursday, September 10th. Rosenblatt Securities set a $60.00 target price on Pharvaris in a research note on Wednesday, September 9th. HC Wainwright reiterated a “buy” rating and set a $60.00 target price on shares of Pharvaris in a report on Tuesday, September 8th. Finally, Oppenheimer reissued an “outperform” rating and set a $75.00 price target on shares of Pharvaris in a research report on Tuesday, September 8th. Thirteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $59.87.

Pharvaris Company Profile

Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.

Pharvaris’ lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.